Dual-Energy Computed Tomography-Based Radiomics to Predict Peritoneal Metastasis in Gastric Cancer

Yong Chen†, Wenqi Xi‡, Weiwu Yao§, Lingyun Wang†, Zhihan Xu¶, Michael Wels¶, Fei Yuan*, Chao Yan* and Huan Zhang*

1 Department of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, 2 Department of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, 3 Department of Radiology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, 4 Department of DI CT Collaboration, Siemens Healthineers Ltd, Shanghai, China, 5 Department of Diagnostic Imaging Computed Tomography Image Analytics, Siemens Healthcare GmbH, Forchheim, Germany, 6 Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, 7 Department of Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Objective: To develop and validate a dual-energy computed tomography (DECT) derived radiomics model to predict peritoneal metastasis (PM) in patients with gastric cancer (GC).

Methods: This retrospective study recruited 239 GC (non-PM = 174, PM = 65) patients with histopathological confirmation for peritoneal status from January 2015 to December 2019. All patients were randomly divided into a training cohort (n = 160) and a testing cohort (n = 79). Standardized iodine-uptake (IU) images and 120-kV-equivalent mixed images (simulating conventional CT images) from portal-venous and delayed phases were used for analysis. Two regions of interest (ROIs) including the peritoneal area and the primary tumor were independently delineated. Subsequently, 1691 and 1226 radiomics features were extracted from the peritoneal area and the primary tumor from IU and mixed images on each phase. Boruta and Spearman correlation analysis were used for feature selection. Three radiomics models were established, including the R_IU model for IU images, the R_MIX model for mixed images and the combined radiomics model (the R_comb model). Random forest was used to tune the optimal radiomics model. The performance of the clinical model and human experts to assess PM was also recorded.

Results: Fourteen and three radiomics features with low redundancy and high importance were extracted from the IU and mixed images, respectively. The R_IU model showed significantly better performance to predict PM than the R_MIX model in the training cohort (AUC, 0.981 vs. 0.917, p = 0.034). No improvement was observed in the R_comb model (AUC = 0.967). The R_IU model was the optimal radiomics model which showed no overfitting in the testing cohort (AUC = 0.967, p = 0.528). The R_IU model demonstrated significantly higher predictive value on peritoneal status than the clinical model and human experts in the testing cohort (AUC, 0.785, p = 0.005; AUC, 0.732, p <0.001, respectively).
INTRODUCTION

Gastric cancer (GC) is a serious health problem worldwide, accounting for estimated 783,000 deaths in 2018 (1). Peritoneal dissemination is the most frequent metastasis for GC. Even for patients receiving radical surgery, peritoneal metastasis (PM) occurs in up to 50% of patients, with median overall survival of 5 to 16 months (2–4). For patients with PM, upfront resection is not recommended for its uncertain benefit (5). New treatment strategies, such as intraperitoneal chemotherapy and extensive intraoperative peritoneal lavage, is of improved prognosis for those patients (6–9). Therefore, early and accurate detection for peritoneal metastasis is of an urgent need to adopt appropriate treatment to improve the prognosis for patients.

Currently, staging laparoscopy along with peritoneal lavage cytology is recommended to evaluate PM, especially for patients with radiographically suspicious signs (5, 10). However, due to invasiveness, limited sensitivity, and cost-effectiveness concerns, those tools are not universally applied (11, 12). Computed tomography (CT) is the cornerstone for clinically staging GC and is commonly used to detect PM. Nevertheless, low sensitivity hinders the role of CT, for a considerable proportion of cases are demonstrated as occult PM (13). Given biological heterogeneity into gastric tumors, a full understanding of PM is under exploration and no clinical or pathological characteristics could accurately present peritoneal spread (2). Therefore, it is of significant benefit to improve the detection of PM if a non-invasive, easy-to-use and representative tool is developed.

One vital shortcoming for multi-detector CT is its limited power to discriminate elemental compositions in materials, which share the same CT values due to its single-energy imaging. On the contrary, dual-energy computed tomography (DECT) allows quantification of different densities in mixed materials by obtaining two different energy levels (14). Applications of DECT in GC have helped to evaluate tumor invasion depth and stage migration rate, predicting lymph node metastasis and tumor response to treatment (15–18). Artificial intelligence (AI) especially deep learning has gained attention to investigate its predictive value of PM (19–21), but the interpretation is under elucidated due to its nature of “black box”. Radiomics is another emerging AI area to investigate tumor heterogeneity by extracting and analyzing high-throughput quantitative imaging features (22). Accumulated researches have explored the value of radiomics in gastric cancer, such as tumor staging, treatment response and prognosis (23–26). However, the application that integrates DECT and radiomics in GC is limited and the added value of DECT-based radiomics to detect PM is under elucidated.

PM, especially for peritoneal micro-metastasis, which is unseen by naked eyes, perhaps could be detected by DECT based on radiomics. Therefore, in this study, we aimed to develop and validate a DECT radiomics model to predict PM. For comparison, we also performed a simulated conventional CT based radiomics model. The diagnostic value of clinical factors and radiologists was also evaluated.

METHODS AND MATERIALS

Patients

Patients were retrospectively and consecutively recruited from Ruijin Hospital (Shanghai, China) from January 2015 to December 2019. Inclusive criteria were as follows: 1) pathologically confirmed as pT3 or pT4 gastric adenocarcinoma; 2) underwent DECT scan less than one week before confirmed PM by laparoscopy, lavage cytology or surgery; 3) no previous anticancer treatment; 4) no previous abdominal surgery or peritonitis. Exclusive criteria were as follows: 1) undetected primary tumor on CT imaging; 2) unsatisfied quality of images due to insufficient stomach distention or motion artifact; 3) concurrent cancers. A total of 239 patients enrolled in this study (70 females; mean age, 62.9 years old, from 27 to 85). Patients with suspicious peritoneal implants or ascites during surgery were further evaluated by pathologists through biopsy slices or lavage cytology. The ultimate confirmation of PM relied on the consensus between involved pathologists and surgeons, according to the AJCC (American Joint Committee on Cancer) guidelines.

Finally, 65 patients and 174 patients were confirmed as PM and non-PM, respectively. Those patients were divided into a training cohort (n = 160) and a testing cohort (n = 79) at a ratio of 2:1 according to computer random. Baseline clinical factors included location, tumor size (cm) and depth of tumor invasion (cT) of the primary tumor, lymph node status (cN), differentiation status, Bormann type and levels of carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125) and carbohydrate antigen 199 (CA199). The definitions for those clinical factors are implemented in Supplementary Material. The flowchart for patient recruitment and framework for the study are presented in Figures 1 and 2.

Abbreviations: AI, artificial intelligence; AJCC, American Joint Committee on Cancer; AUC, area under the curve; CA125, carbohydrate antigen 125; CA199, carbohydrate antigen 199; CEA, carcinoembryonic antigen; CI, confidence interval; DCA, decision curve analysis; DECT, dual-energy computed tomography; GC, gastric cancer; ICC, intra-class coefficient; IU, iodine uptake; NPV, negative predictive value; PCI, peritoneal cancer index; PM, peritoneal metastasis; PPV, positive predictive value; RF, random forest; ROC, receiver operating characteristic curve; ROI, region of interest.
**Imaging Protocol**

All patients underwent DECT scan less than one week before confirmed PM by either of two scanners (Siemens SOMATOM Definition Flash or SOMATOM Force, Siemens Healthineers) after fasting overnight. Images from portal-venous and delayed phases were processed by dual-energy software (Syngo.via, Version VB10, Siemens Healthineers) to acquisition 120-kV equivalent mixed images. The imaging protocol and dual-energy post processing were described in our previous study (27) and detailed information is presented in Supplementary S2. Then the images were used for post-processing by delivering to a dedicated workstation with dual-energy software (Syngo.via, Version VB20, Siemens Healthineers). Apart from the mixed images, the iodine-uptake (IU) images for portal-venous phase and delayed phase were reconstructed and obtained from the dual-energy datasets (28). The mixed images and the IU images based on both portal-venous phase and delayed phase were ultimately acquired for further delineation and analysis.

**Standardization for Iodine Concentration**

For iodine concentration images, iodine quantitation was standardized in an in-house software (iodine standardization, Syngo via). The purpose of iodine standardization was to reduce the influence of technical or physiological differences resulting from variational cardiac output and phase time when loading iodine within tissues (29). A circular ROI inside the abdominal aorta was independently outlined for individuals on the portal-venous phase and delayed phase from the IU images, omitting calcified plaque secondary to atherosclerosis. The rest tissues in this image slice were used as the background to compare with the reference iodine concentration from the abdominal aorta (nIC = IBackground/ICaorta). The standardized IU images generalized were then used for masking and analyzing.

**Segmentation**

The segmentation was completed by one senior radiologist with ten years of experience in abdominal imaging, who was aware of the gastric tumor but blinded to the clinical and pathological information. The delineation was performed using an open-source software 3d-slicer (version 4.10.1) on the mixed images on the portal-venous and delayed phases, respectively. Two regions of interest (ROIs), including the peritoneal area and the primary tumor, were independently segmented. For the ROI of the primary tumor, the largest slice of the tumor on the axial image was manually segmented along with the edge of the tumor, avoiding gastric cavity and perigastric fat. For the peritoneal ROI, the delineation was performed according to abdominal regions, which consisted of the upper abdomen, the middle abdomen and the lower abdomen. The anatomical landmarks of the three regions included the upper liver, the lower costal arch, the upper sacroiliac joint and the pubic symphysis. Peritoneal ROIs were segmented at the middle slice of each abdominal region. The peritoneal area on the largest slice of the primary tumor was also included. As a candidate indicator for PM, ascites was also segmented if there was any in the peritoneal cavity. Therefore, the peritoneal ROI for each patient included four slices. The peritoneal ROI was semi-automatically segmented by setting a priori threshold ranging from -150HU to 50HU. The images along with the ROI were in register to the IU images to wipe off potential vessels in the peritoneal area. The ROIs delineated on the mix images were also matched to the IU images, guaranteeing they shared with the same slices. Therefore, for mixed or IU images, each had four ROIs (two on the portal-venous phase and two on the delayed phase).

**Feature Extraction**

Before feature extraction, all images underwent uniform preprocessing, including resampling and filtering (see Supplementary S3). Radiomics features were firstly extracted from the original images and then extracted from the filtering images. Finally, there were 1691 and 1226 radiomics features extracted from the ROI of the peritoneal area and the primary tumor, respectively. All radiomics features were in accordance with the image biomarker standardization initiative (30). Detailed information on feature extraction is implemented in Supplementary S3.
Reliability Analysis
We performed a reliability test to guaranteeing the reproducibility and robustness of the radiomics features. Sixty patients were randomly selected and one junior radiologist with five years of experience in abdominal imaging repeated the segmentation aforementioned. Given the same ROI of the IU and mixed images, we chose the mixed images for reliability analysis. Intra-class coefficient (ICC) was used to evaluate the reliability between the two radiologists. Radiomics features with ICCs above 0.75 were considered as good reliability.

Dimensionality Reduction
To overcome potential overfitting, a step-wise process for feature selection was performed in the training cohort. First, Boruta was used to choose relevant features to peritoneal status. Boruta is a wrapper algorithm that selects relevant features by comparing the original importance of attributes, estimated using their permuted copies (31). To avoid randomness, the importance of each feature was calculated with 100 iterations and then a mean importance was generated. Features with the highest mean importance were defined as the confirmed features and remained. The features selected from Boruta would have highly relevant and redundant. Therefore, in the second step, we calculated the Spearman correlation coefficients for those features. Highly correlated features were clustered into the same subgroup using unsupervised clustering algorithm and feature with the highest mean importance in each subgroup was considered as the representative feature for further modeling. Consequently, features selected from the step-wise method would have high contribution and low redundancy and were included in the following modeling.

Modeling
Radiomics features selected from IU and mixed images were independently used for modeling (the R_IU model and the R_MIX model) to discriminate PM and non-PM in the training cohort. To select the optimal radiomics model, we also built a combined model (the R_comb model) integrating IU and mixed features. Random forest (RF) algorithm with 10-fold cross-validation parameter tuned by grid search approach was implemented for model establishments. The performance of the radiomics models was then validated in the testing cohort. The weight of the features in each radiomics model were evaluated by importance ranking via the Gini impurity using RF.
Model Comparison
The optimal radiomics model was in comparison with a clinical model constructed by clinical risk factors. The performance of human experts to assess PM was also recorded for all patients. Two senior radiologists who major in abdominal imaging for more than 10 years of experience independently reevaluated the peritoneal status based on CT imaging. They have informed the patients of GC but aware of the clinical and pathological information. The consensus between the radiologists was recorded and if there was any disagreement, the final decision was made by the discussion. The performance of the radiomics model, the clinical model, human experts was compared in both cohorts.

Clinical Use
The goodness of fit for those models was evaluated to observe the agreement between the actual probability and the predicted probability made by those models. Decision curve analysis (DCA) was implemented to show the net clinical benefits of all models to predict peritoneal status.

Statistics
Continuous variables were compared by independent-sample t-test or Mann-Whitney U test based on their distribution. Categorical variables were compared using $\chi^2$ or Fisher's exact test. RF was tuned by Grid search with 10-fold cross validation. Discriminative metrics for peritoneal status included receiver operating characteristic (ROC) curve, area under the curve (AUC), accuracy, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV). 95% Confidence interval (CI) for each metrics was also recorded. AUCs comparison was examined by the Delong test. The goodness of fit for models was assessed and the deviation was evaluated by the Brier score. The consensus between the radiologists to evaluate peritoneal status was estimated by the kappa coefficient. The strength of kappa coefficients with 0 to 0.20, 0.21 to 0.40, 0.41 to 0.60, 0.61 to 0.80 and 0.81 to 1 was interpreted as slight, fair, moderate, substantial and almost perfect. All statistical analysis was performed with R (version 3.6.0) and Python (version 3.7). Package resources are listed in Supplementary Table S1. A significant difference was achieved if a two-side p-value < 0.05.

RESULTS
Patients Baseline Information
No selective bias was found in terms of the positive rate of PM between the training cohort and the testing cohort (26.9% vs. 27.8%, p = 0.874). Age and gender also presented no significant bias between the two cohorts (p = 0.913 and 0.848, respectively). For patients in the training cohort, gender, ascites, tumor size, differentiation status, and Bormann type showed a significant difference to discriminate the peritoneal status (all p < 0.05). For patients in the testing cohort, age, ascites, tumor size, invasion of tumor depth, and differentiation status showed statistically different to predict the peritoneal status (all p < 0.05). The other clinical factors indicated no significant difference in both cohorts (see Table 1). Indices that showed a significant difference in the training cohort were considered as clinical risk factors and were used for modeling using the multivariate logistic regression.

Reliability Analysis
For features extracted from the portal-venous phase, 213 and 138 radiomics features showed robust with an ICC higher than 0.75 for the peritoneal area and the primary tumor, respectively. As for features from the delayed phase, 523 and 189 radiomics features showed robust with an ICC higher than 0.75 for the peritoneal and the primary tumor, respectively. Therefore, for the IU and mixed images, each had 1063 reliable radiomics features for further analysis.

Dimensionality Reduction
There were 31 and 37 confirmed features after Boruta analysis from IU and mixed images, respectively (Figures 3A, B). Given high redundancy among those features, Spearman correlation analysis was performed. Unsupervised clustering indicated 14 and 3 subgroups generated for features from the IU and mixed images (Figures S1 and S2). Finally, 14 and 3 features were selected for each image set by the mean importance of each feature. After tuned by RF, all the 14 radiomics features from IU images were used for RF modeling to construct the R_IU model. Similarly, the three features from mixed images were finally used to establish the R_MIX model through the RF algorithm.

To build the R_comb model, we further integrated the 14 features from the IU images with the three features from the mixed images. The correlation coefficients of those 17 features were also calculated and no redundancy was observed (Figure S3). After tuned by RF, eight features were considered as important and used for modeling the R_comb model.

Consequently, the radiomics features selected by the step-wise method showed little redundant and highly important. For each model, the most important feature was coincidently from the peritoneal area. The importance ranking of those features in each model are implemented in Figure 4.

The Performance of Radiomics Models
The R_IU model showed power ability to predict PM for the gastric tumor in the training cohort, achieving an AUC of 0.981 (95%CI, 0.961-0.995) and accuracy of 95%. It also presented a considerable sensitivity and specificity (90.7% and 96.6%, respectively). This model showed good generalization by applying it to differentiate peritoneal status in the testing cohort, with an AUC of 0.967 (95% CI, 0.931-1). No overfitting was observed for the R_IU model in the testing cohort (p = 0.528). The other discriminative metrics also demonstrated a good diagnostic value of the R_IU model in the testing cohort. Detailed information on discriminative metrics is implemented in Table 2.

The R_MIX model showed inferior to the R_IU model in both cohorts. For patients in the training cohort, the R_MIX model reached an AUC of 0.917 (0.860-0.974) and an accuracy of 94.4%. For patients in the testing cohort, the R_MIX model reached an AUC and accuracy of 0.894 (0.800-0.988) and 84.8%, respectively. The R_IU model was significantly better than the R_MIX model to discriminate PM in the training cohort (p = 0.034).
The R_comb model did not improve the performance compared with the R_IU model in both cohorts, with AUCs of 0.955 (95%CI, 0.904-1) and 0.961 (95%CI, 0.918-1), respectively. Other information on discriminative metrics of the R_comb model is implemented in Table 2.

Overall, we considered the R_IU model as the optimal radiomics model and used it as the representative for further analysis.

**Comparison With the Clinical Model and Human Experts**

ROC curve of each model in both cohorts was visualized in Figures 5 A, B. Gender and ascites were indicated as independent risk factors in the multivariate logistic regression (p = 0.025 and 0.018, respectively). The clinical model showed the significantly poor performance to predict peritoneal status compared with the R_IU model in both cohorts (the training cohort, AUC: 0.847 vs. 0.981, p < 0.001; the testing cohort, AUC: 0.785 vs. 0.967, p = 0.005).

The consensus between the two human experts was almost perfect, with a kappa value of 0.83. There were 10 (5.7%) and 31 (47.7%) patients misclassified by human experts in the non-PM and PM groups, respectively. For patients in the training and testing cohorts, there were 13 and 31 patients demonstrating radiological suggestion of peritoneal metastasis, respectively. The human experts reached AUCs of 0.733 (95%CI, 0.654-0.812) and 0.732 (95%CI, 0.623-0.842) to evaluate PM in the training and

---

**Table 1** Baseline clinical characteristics for patients in the training and testing cohorts.

|                  | The training cohort | The testing cohort |
|------------------|---------------------|--------------------|
|                  | non-PM (n = 117) | PM (n = 43) | non-PM (n = 57) | PM (n = 22) |
| **Gender**       |                     |   |                     |   |
| Female           | 26 (22.2%)          | 20 (46.5%) | 15 (26.3%)         | 9 (40.9%) |
| Male             | 91 (77.8%)          | 23 (53.5%) | 42 (73.7%)         | 13 (59.1%) |
| **Age**          | 65.0 (59.0, 70.0)   | 65.0 (52.5, 69.0) | 68.0 (60.0, 74.0) | 53.5 (43.2, 57.0) |
| Location         |                     |   |                     |   |
| Fundus and Cardia| 15 (12.8%)          | 2 (4.7%)   | 7 (12.3%)          | 1 (4.6%)   |
| Body             | 23 (19.7%)          | 12 (27.9%) | 13 (22.8%)         | 8 (36.4%)  |
| Antrum and pylorus| 49 (41.9%)          | 13 (30.2%) | 27 (47.4%)         | 5 (22.7%)  |
| Diffuse          | 30 (25.6%)          | 16 (37.2%) | 10 (17.5%)         | 8 (36.4%)  |
| **Ascites (ml)** |                     |   |                     |   |
| No ascites       | 94 (80.3%)          | 18 (41.9%) | 48 (84.2%)         | 7 (31.8%)  |
| Ascites < 50     | 22 (18.8%)          | 19 (44.2%) | 9 (15.8%)          | 12 (54.5%) |
| Ascites > 50     | 1 (0.9%)            | 6 (14.0%)  | 0 (0.0%)           | 3 (13.6%)  |
| **Tumor size (cm)** | 4.6 (3.7, 5.8)   | 5.5 (4.7, 7.0) | 4.4 (3.6, 5.6) | 6.2 (5.2, 8.4) |
| **Tumor invasion**|                     |   |                     |   |
| cT2              | 2 (1.7%)            | 0 (0.0%)   | 0 (0.0%)           | 1 (4.6%)   |
| cT3              | 6 (5.1%)            | 1 (2.3%)   | 4 (7.0%)           | 0 (0.0%)   |
| cT4a             | 80 (68.4%)          | 24 (55.8%) | 41 (71.9%)         | 11 (50.0%) |
| cT4b             | 29 (24.8%)          | 18 (41.9%) | 12 (21.1%)         | 10 (45.5%) |
| **Node lymph status** |                  |   |                     |   |
| n0               | 22 (18.8%)          | 8 (18.6%)  | 9 (15.8%)          | 3 (13.6%)  |
| n1               | 33 (28.2%)          | 8 (18.6%)  | 24 (42.1%)         | 6 (27.3%)  |
| n2               | 47 (40.2%)          | 17 (39.5%) | 18 (31.6%)         | 10 (45.5%) |
| n3a              | 11 (9.4%)           | 5 (11.6%)  | 5 (8.8%)           | 1 (4.6%)   |
| n3b              | 4 (3.4%)            | 5 (11.6%)  | 1 (1.8%)           | 2 (9.1%)   |
| **Differentiation status** |                |   |                     |   |
| High             | 1 (0.9%)            | 0 (0.0%)   | 0 (0.0%)           | 0 (0.0%)   |
| Medium           | 19 (16.2%)          | 0 (0.0%)   | 11 (19.3%)         | 0 (0.0%)   |
| Low              | 89 (76.1%)          | 41 (95.3%) | 44 (77.2%)         | 18 (81.8%) |
| SRCC             | 8 (6.8%)            | 2 (4.7%)   | 2 (3.5%)           | 4 (18.2%)  |
| **Bormann**      |                      |   |                     |   |
| I                | 3 (2.6%)            | 2 (4.7%)   | 2 (3.5%)           | 1 (4.6%)   |
| II               | 46 (39.3%)          | 10 (23.3%) | 22 (38.6%)         | 5 (22.7%)  |
| III              | 66 (55.6%)          | 25 (58.1%) | 30 (52.6%)         | 12 (54.5%) |
| IV               | 3 (2.6%)            | 6 (14.0%)  | 3 (5.3%)           | 4 (18.2%)  |
| **CEA**          |                      |   |                     |   |
| Negative         | 103 (88.0%)         | 36 (83.7%) | 50 (87.7%)         | 20 (90.9%) |
| Positive         | 14 (12.0%)          | 7 (16.3%)  | 7 (12.3%)          | 2 (9.09%)  |
| **CA199**        |                      |   |                     |   |
| Negative         | 58 (49.6%)          | 30 (69.8%) | 37 (64.9%)         | 12 (54.5%) |
| Positive         | 59 (50.4%)          | 13 (30.2%) | 20 (35.1%)         | 10 (45.5%) |
| **CA125**        |                      |   |                     |   |
| Negative         | 74 (63.2%)          | 30 (69.8%) | 33 (57.9%)         | 13 (59.1%) |
| Positive         | 43 (36.8%)          | 13 (30.2%) | 24 (42.1%)         | 9 (40.9%)  |

CA125, carbohydrate antigen 125; CA199, carbohydrate antigen 199; CEA, carcinoembryonic antigen; PM, peritoneal metastasis.
testing cohorts, respectively. The sensitivity and specificity of human experts in the training cohort was 53.5% (37.8%-68.5%) and 93.2% (86.6%-96.8%), respectively. The sensitivity and specificity in the testing cohort was 50% (28.8%-71.2%) and 96.5% (86.8%-99.4%), respectively. The R_IU model showed significantly more power to differentiate peritoneal status than the human experts did in both the cohorts (both p < 0.001).

Clinical Use and Calibration

The DCA curve showed similar good clinical benefit for patients if preoperatively diagnosing them using the R_IU model and the R_comb model, which were better than the other models (Figure 5C). Analysis of goodness of fit also demonstrated the R_IU model was robust to evaluate peritoneal status in both cohorts (Brier score = 0.051 and 0.055, respectively).
DISCUSSION

In this study, we developed and validated a DECT-derived radiomics model to predict peritoneal dissemination for GC, which outperformed the clinical model and human experts. The non-invasive and easy-to-use radiomics biomarker showed clinical benefit, which provided potentiality for GC patients with PM to avoid unnecessary surgery and adjust for new treatment strategies.

Previous studies have revealed the diagnostic value of radiomics for PM in GC based on conventional CT derived radiomics, with AUCs in the range of 0.724 to 0.873 in the validation cohort (32–34). In our study, similar performance was also observed in the R_MIX model built by 120kV-equivalent
mix images in the testing cohort, with an AUC of 0.894. More importantly, our study demonstrated iodine-uptake derived radiomics provided more powerful value to predict PM than the conventional one. DECT is a candidate modality to apply in the gastric tumor due to its insight into materials decomposition (29). Our previous researches have introduced the role of DECT combined with PET/CT in dynamically monitoring the process of peritoneal metastasis for GC in vitro (35). In this study, we demonstrated the DECT-derived radiomics could accurately diagnosing PM for GC patients. DECT provides the possibility of materials decomposition. The R-IU model significantly outperformed the R-MIX model in the testing cohort, demonstrating the superiority of the iodine images. On the other hand, although AUC and sensitivity were not improved in the R_comb model compared with the R-IU model in the testing cohort, other discrimination metrics (i.e., accuracy, specificity, PPV and NPV) showed slightly better in the R_comb model, indicating the necessity for a synthesis of two models to predict PM in GC. The combination of materials decomposition brought from iodine images as well as mixed images and radiomics could probably detect micro-metastasis and tumor heterogeneity of GC.

The radiomics model also significantly outperformed the clinical model in diagnosing PM in both cohorts. It was reported that females were susceptible to peritoneal dissemination (36). In this study, we also found gender was an independent risk factor in the multivariable logistic regression and females were with significantly increased risk for PM. Ascites are an important predictor for PM. It was reported that the possibility of PM reached 75% to 100% if more than 50ml of ascites was manifested in CT (37, 38). In our study, ascites was an independent risk factor to indicate PM (p < 0.001) and the degree of it was strongly correlated with PM. We also found tumor size, differentiation status, Bormann type and CA199 showed significance between PM and non-PM groups in the univariable analysis but not presented as independent risk factors. The clinical model integrated those clinical and pathological parameters achieved a moderate performance to discriminate PM and non-PM, indicating limited specificity of those variables.

The peritoneal status evaluated by human experts was also unsatisfactory comparing to the R_IU model. CT is the recommended modality to preoperatively staging GC and evaluate peritoneal status with high specificity of 96.2% to 99% (13, 39). However, due to micro-metastasis undetectable in CT, the sensitivity was limited in a range of 25% to 50.9% (13, 36). In this study, we reevaluated the preoperative status of the peritoneum and similar performance was observed as previous reported (sensitivity and specificity, 50%-53.5% and 93.2%-96.5%). Nevertheless, our R_IU model was significantly better than human experts to predict PM in both cohorts, especially with improved sensitivity, probably indicating the advantage of the radiomics model to discern occult PM.

We simultaneously outlined and analyzed the primary tumor as well as the peritoneal area for the radiomics process. Notably, we segmented ROIs on 2D instead of 3D slices (which is much...
time-consuming), for a multi-center study has demonstrated that models built by 2D radiomic features revealed similar performance in evaluating preoperative characteristics of GC compared with those built by 3D features (40). Nevertheless, to utmost capture information of peritoneum, we delineate the peritoneal ROIs according to the anatomical distribution of the peritoneal cancer index (PCI) (41). PCI is used to assess the extent of peritoneal dissemination and is considered as a prognostic indicator for patients with peritoneal carcinomatosis, thus providing vital information for patient management and treatment tailor for patients with gastric tumor (42, 43).

However, laparotomy is a must to evaluate PCI. The peritoneal ROIs were simulated as PCI, and for simplification, we chose three representative cross-sectional slices to inflect PCI. We also delineated the peritoneal area where the largest slice of the primary tumor settled, for the initial metastasis probably occurs in this area according to the “seed and soil” hypothesis (44). In the three radiomics model, the most important feature in each model was unlimitedly from the peritoneal area, indicating the unneglectable role of peritoneum in delineation and only delineating the primary tumor seems insufficient to assess PM.

Gray-level normalization for medical images is a prerequisite against discretization and for feature robustness to ensure radiomics as a reliable biomarker (45, 46). In this study, the iodine images were standardized to decrease the individual circulation variation resulting from technical reasons and patients, helping to reconstruct uniform iodine-uptake images and normalize variable gray levels. Previous studies reported the standardization of iodine concentration was beneficial to staging tumors and evaluating treatment response (47–49). Unlike standardizing iodine uptake by comparing the concentration between tumors and aorta, we compared the iodine concentration between background tissues to the aorta. This method was probably representative to normalize an individual’s iodine uptake effecting on gray-level normalization of the whole images and thus equally treated ROIs for both the primary tumor and the peritoneal regions.

Our study has several limitations. First, this is a single-center study and the sample size is limited, therefore, the generalization...
of the DECT derived radiomics needs further external validation. Meanwhile, the retrospective nature of the study probably introduced selective bias for patients. Second, due to time-consuming, delineation for the entire peritoneum area was abandoned, which may omit potential metastasis in the peritoneal area. Furthermore, it was worth noting that considering the real-world clinical setting, part of the patients enrolled in our study were radiologically suggestive as the peritoneal spread, which could improve the performance of the radiomics model. Besides, Lauren classification especially the diffuse subtype was considered as a risk factor for peritoneal spread (34, 50). In this study, this parameter was abandoned because it was unavailable to a few patients who were transferred to our hospital for upfront resection and the biopsy was unavailable before surgery. Our clinical model demonstrated limited power of those parameters to predict peritoneal status and the value of Lauren type to represent PM is undermined due to high tumor heterogeneity of GC (2). Lastly, the biological meaning of the radiomics features selected remain elucidation.

In summary, the DECT based radiomics model is a noninvasive, easy-to-use and representative tool to preoperatively predict PM for GC, which of significant benefit to adopt appropriate treatment to improve the prognosis for those patients.

DATA AVAILABILITY STATEMENT

The datasets generated in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Ethics Committee of Ruijin Hospital. The ethics committee waived the requirement of written informed consent for participation.

AUTHOR CONTRIBUTIONS

Conceptualization, HZ, CY, and FY. Methodology, ZX and WX. Software, MW. Validation, YC and ZX. Formal analysis, WY. Investigation, LW. Resources, HZ and FY. Data curation, YC and WX. Writing—original draft preparation, YC. Writing—review and editing, HZ and WY. Visualization, ZX. Supervision, HZ. Project administration, FY. Funding acquisition, HZ, CY, and WY. All authors contributed to the article and approved the submitted version.

FUNDING

This work was funded by Shanghai Science and Technology Commission Science and Technology Innovation Action Clinical Innovation Field (no. 18411953000), Medical Engineering Cross Research Foundation of Shanghai Jiaotong University (no. YG2019ZDB09), the National Natural Science Foundation of China (no. 817171789, 817171790 and 81772518), and Multicenter Clinical Trial of Shanghai Jiao Tong University School of Medicine (no. DLY2016062). The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2021.659981/full#supplementary-material

REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer J Clin (2018) 68 (6):394–424. doi: 10.3322/caac.21492
2. Chen Y, Zhou Q, Wang H, Zhao W, Ding Y, Lu J, et al. Predicting Peritoneal Dissemination of Gastric Cancer in the Era of Precision Medicine: Molecular Characterization and Biomarkers. Cancers (Basel) (2020) 12(8):2236. doi: 10.3390/cancers12082236
3. Shiozaki H, Elimova E, Slack RS, Chen HC, Staeckel GA, Neige N, et al. Prognosis of Gastric Adenocarcinoma Patients With Various Burdens of Peritoneal Metastases. J Surg Oncol (2016) 113(1):29–35. doi: 10.1002/jso.24087
4. Cocolinli F, Gheza F, Lotti M, Virzi S, Iusco D, Ghemardi C, et al. Peritoneal Carcinomatosis. World J Gastroenterol (2013) 19(41):6979–94. doi: 10.3748/wjg.v19.141.6979
5. National Comprehensive Cancer Network. Gastric Cancer. Version 4.2020. Available at: https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf (accessed on 14 August 2020).
6. Guo J, Xu A, Sun X, Zhao X, Xia Y, Rao H, et al. Combined Surgery and Extensive Intraoperative Peritoneal Lavage vs Surgery Alone for Treatment of Locally Advanced Gastric Cancer: The Seiphus Randomized Clinical Trial. JAMA Surg (2019) 154(7):610–6. doi: 10.1001/jamasurg.2019.0153
7. Kim G, Chen E, Tay AY, Lee JS, Phua JN, Shabbir A, et al. Extensive Peritoneal Lavage After Curative Gastrectomy for Gastric Cancer (EXPEL): Study Protocol of an International Multicentre Randomised Controlled Trial. Ips J Clin Oncol (2017) 47(2):179–84. doi: 10.1093/ijccm/nwx153
8. Misawa K, Mochizuki Y, Ohashi N, Matsui T, Nakayama H, Tsuboi K, et al. A Randomized Phase III Trial Exploring the Prognostic Value of Extensive Intraoperative Peritoneal Lavage in Addition to Standard Treatment for Resectable Advanced Gastric Cancer: CCOG 1102 Study. Ips J Clin Oncol (2014) 44(1):101–3. doi: 10.1093/jcco/oyt157
9. Kuramoto M, Shimada S, Ikeshima S, Matsu A, Yagi Y, Matsuda M, et al. Extensive Intraoperative Peritoneal Lavage as a Standard Prophylactic Strategy for Peritoneal Recurrence in Patients With Gastric Carcinoma. Ann Surg (2009) 250(2):242–6. doi: 10.1097/SLA.0b013e3181b6e80e
10. Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D, et al. Gastric Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Ann Oncol (2016) 27(suppl 5):v38–49. doi: 10.1093/annonc/mdw350
11. Zhang Y, Zhao J, Yu H, Li P, Liang W, Liu Z, et al. Detection and Isolation of Free Cancer Cells From Ascites and Peritoneal Lavages Using Optically

May 2021 | Volume 11 | Article 659981
27. Shi C, Liu B, Yan J, Liu H, Pan Z, Yao W, et al. Gastric Cancer: Preoperative Management. J Surg Oncol (2018) 117(6):1288-96. doi: 10.1002/jso.24942

28. Albrecht MH, Trommer J, Wichmann JL, Scholtz JE, Martin SS, Lehnert T, et al. Peritoneal Metastasis: Detection With 16- or 64-Detector Row CT in Patients Undergoing Surgery for Gastric Cancer. Radiology (2009) 253(2):407-15. doi: 10.1148/radiol.2532082272

29. Xu JJ, Taudorf M, Valkers M, Abdala MA, Aerts H, Andreareczyk V, Apte A, et al. The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-Based Phenotyping. Radiology (2020) 295(2):328-38. doi: 10.1148/radiol.2020191145

30. Liu S, He J, Liu S, Ji C, Guan W, Chen L, et al. Radiomics Analysis Using Contrast-Enhanced CT for Preoperative Prediction of Occult Peritoneal Metastasis in Advanced Gastric Cancer. Eur Radiol (2020) 30(1):239-46. doi: 10.1007/s00330-019-06368-5

31. Huang W, Zhou K, Jiang Y, Chen C, Yuan Q, Han Z, et al. Radiomics Nomogram for Prediction of Peritoneal Metastasis in Patients With Gastric Cancer. Front Oncol (2020) 10:1416. doi: 10.3389/fonc.2020.01416

32. Dong D, Tang L, Li ZY, Fang MJ, Gao JB, Shan XH, et al. Development and Validation of an Individualized Nomogram to Identify Occult Peritoneal Metastasis in Patients With Advanced Gastric Cancer. Ann Oncol (2019) 30 (3):431-8. doi: 10.1016/annonc/mdz001

33. Huang W, Zhou K, Jiang Y, Chen C, Yuan Q, Han Z, et al. Radiomics Nomogram for Prediction of Peritoneal Metastasis in Patients With Gastric Cancer. Front Oncol (2020) 10:1416. doi: 10.3389/fonc.2020.01416

34. Dong D, Tang L, Li ZY, Fang MJ, Gao JB, Shan XH, et al. Development and Validation of an Individualized Nomogram to Identify Occult Peritoneal Metastasis in Patients With Advanced Gastric Cancer. Ann Oncol (2019) 30 (3):431-8. doi: 10.1016/annonc/mdz001

35. Shi B, Lin H, Zhang M, Lu W, Qu Y, Zhang H. Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings From Dual Energy CT and PET/CT. J Vis Exp (2018) 131:52516. doi: 10.3791/56526

36. Murak Kaya D, Noguera-Gonzalez GM, Harada K, Akiyama FC, Roy-Chowdhuri S, Estrella S, et al. Risk of Peritoneal Metastases in Patients Who Had Negative Peritoneal Staging and Received Therapy for Localized Gastric Adenocarcinoma. J Surg Oncol (2018) 117(4):678-84. doi: 10.1002/jso.24912

37. Yajima K, Kanda T, Ohashi M, Waki T, Nakagawa S, Sasamoto R, et al. Clinical and Diagnostic Significance of Preoperative Computed Tomography Findings of Ascites in Patients With Advanced Gastric Cancer. Am J Surg (2006) 192(2):185-90. doi: 10.1016/j.amjsurg.2005.05.007

38. Chang DK, Kim JW, Kim BK, Song CS, Han JK, et al. Clinical Significance of CT-defined Minimal Ascites in Patients With Gastric Cancer. World J Gastroenterol (2005) 11(42):6587-92. doi: 10.3748/wjg.v11.i42.6587

39. Burbridge S, Mahady K, Naik K. The Role of CT and Staging Laparoscopy in Gastric Cancer. Clin Radiol (2013) 68(3):251-5. doi: 10.1016/j.crad.2012.07.015

40. Meng L, Dong D, Chen X, Fang M, Wang R, Li J, et al. 2D and 3D CT Radiomic Features Performance Comparison in Characterization of Gastric Cancer: A Multi-Center Study. IEEE J BioMed Health Inform (2021) 25 (3):755-63. doi: 10.1109/JBMHI.2020.3002805

41. Jacquet P, Sugarbaker PH. Clinical Research Methodologies in Diagnosis and Staging of Patients With Peritoneal Carcinomatosis. Cancer Treat Rev (1996) 22:359-74. doi: 10.1016/0305-7372(96)00027-6

42. Shi-Fuq-Ul-Hassan M, Zhang G, Latifi K, Ullah G, Hunter DC, Balagurunathan Y, et al. Intrinsic Dependencies of CT Radiomic Features on Voxel Size and Number of Gray Levels. Med Phys (2017) 44(3):1050-62. doi: 10.1002/mp.12123

43. Shi-Fuq-Ul-Hassan M, Latifi K, Zhang G, Ullah G, Gildies R, Moros E. Voxel Size and Gray Level Normalization of CT Radiomic Features in Lung Cancer. Sci Rep (2018) 8(1):10545. doi: 10.1038/s41598-018-28895-9

44. Pan Z, Pang L, Ding B, Yan C, Zhang H, Du L, et al. Gastric Cancer Staging of Patients With Peritoneal Carcinomatosis. J Clin Oncol (2016) 34(2):171-7. doi: 10.1200/JCO.2015.65.0561

45. Chen XH, Ren K, Liang P, Chai YR, Chen KS, Gao JB. Spectral Computed Tomography in Advanced Gastric Cancer: Can Iodine Concentration non-Invasively Assess Angiogenesis? World J Gastroenterol (2017) 23(9):1666–75. doi: 10.3748/wjg.v23.i9.1666
49. Lv P, Liu J, Yan X, Chai Y, Chen Y, Gao J, et al. CT Spectral Imaging for Monitoring the Therapeutic Efficacy of VEGF Receptor Kinase Inhibitor AG-013736 in Rabbit VX2 Liver Tumours. *Eur Radiol* (2017) 27(3):918–26. doi: 10.1007/s00330-016-4458-4

50. Esaki Y, Hirayama R, Hirokawa K. A Comparison of Patterns of Metastasis in Gastric Cancer by Histologic Type and Age. *Cancer* (1990) 65(9):2086–90. doi: 10.1002/1097-0142(19900501)65:9<2086::aid-cncr2820650933>3.0.co;2-b

**Conflict of Interest:** ZX is employed by Siemens Healthineers Ltd. MW is employed by Siemens Healthcare GmbH.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Chen, Xi, Yao, Wang, Wels, Yuan, Yan and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.